High triglyceride-glucose index is associated with poor cardiovascular outcomes in Chinese acute coronary syndrome patients without diabetes mellitus who underwent emergency percutaneous coronary intervention with drug-eluting stents.
acute coronary syndrome
emergency percutaneous coronary intervention
insulin resistance
major adverse cardiovascular and cerebrovascular event
triglyceride-glucose index
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
18
11
2022
accepted:
03
02
2023
entrez:
6
3
2023
pubmed:
7
3
2023
medline:
8
3
2023
Statut:
epublish
Résumé
Previous research has supported the association between the triglyceride-glucose index (TyG index) and the incidence and prognosis of cardiovascular disease. However, the association between the TyG index and the prognosis of patients with acute coronary syndrome (ACS) without diabetes mellitus (DM) who underwent emergency percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) has not been thoroughly investigated, and these patients may easily be neglected. Therefore, this study aimed to investigate the association between the TyG index and major adverse cardiovascular and cerebrovascular events (MACCEs) in Chinese ACS patients without DM who underwent emergency PCI with DES. The total number of ACS patients without DM who underwent emergency PCI with DES for this study was 1650. Ln [fasting triglycerides (mg/dL) ×fasting plasma glucose (mg/dL)/2] is the formula used to calculate the TyG index. According to the TyG index, we classified the patients into two groups. The frequency of the following endpoint events was calculated and compared between the two groups: all-cause death, non-fatal myocardial infarction (MI), non-fatal ischemia stroke, ischemia-driven revascularization and cardiac rehospitalization. After a median of 47 months of follow-up [47 (40, 54)], 437 (26.5%) endpoint events were recorded in total. The TyG index was further demonstrated to be independent of MACCE by multivariable Cox regression analysis (hazard ratio [HR], 1.493; 95% confidence interval [CI], 1.230-1.812; For ACS patients without DM who received emergency PCI with DES, the TyG index might be an independent predictor of MACCE.
Sections du résumé
Background
Previous research has supported the association between the triglyceride-glucose index (TyG index) and the incidence and prognosis of cardiovascular disease. However, the association between the TyG index and the prognosis of patients with acute coronary syndrome (ACS) without diabetes mellitus (DM) who underwent emergency percutaneous coronary intervention (PCI) with drug-eluting stents (DESs) has not been thoroughly investigated, and these patients may easily be neglected. Therefore, this study aimed to investigate the association between the TyG index and major adverse cardiovascular and cerebrovascular events (MACCEs) in Chinese ACS patients without DM who underwent emergency PCI with DES.
Methods
The total number of ACS patients without DM who underwent emergency PCI with DES for this study was 1650. Ln [fasting triglycerides (mg/dL) ×fasting plasma glucose (mg/dL)/2] is the formula used to calculate the TyG index. According to the TyG index, we classified the patients into two groups. The frequency of the following endpoint events was calculated and compared between the two groups: all-cause death, non-fatal myocardial infarction (MI), non-fatal ischemia stroke, ischemia-driven revascularization and cardiac rehospitalization.
Results
After a median of 47 months of follow-up [47 (40, 54)], 437 (26.5%) endpoint events were recorded in total. The TyG index was further demonstrated to be independent of MACCE by multivariable Cox regression analysis (hazard ratio [HR], 1.493; 95% confidence interval [CI], 1.230-1.812;
Conclusion
For ACS patients without DM who received emergency PCI with DES, the TyG index might be an independent predictor of MACCE.
Identifiants
pubmed: 36875470
doi: 10.3389/fendo.2023.1101952
pmc: PMC9975349
doi:
Substances chimiques
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1101952Informations de copyright
Copyright © 2023 Zhang, Chu, Zhong, Luo, Ning and Guo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer LF declared a shared affiliation with the authors YZ, CC, Y-BL, F-FN, and NG to the handling editor at the time of review.
Références
Eur Heart J. 2018 Jan 7;39(2):119-177
pubmed: 28886621
J Am Coll Cardiol. 2020 Feb 11;75(5):525-538
pubmed: 32029136
Diabetes Care. 2011 Jan;34 Suppl 1:S62-9
pubmed: 21193628
Metab Syndr Relat Disord. 2008 Dec;6(4):299-304
pubmed: 19067533
Cardiovasc Diabetol. 2014 Oct 20;13:146
pubmed: 25326814
Endocr Rev. 2019 Dec 1;40(6):1447-1467
pubmed: 31050706
Am J Cardiol. 2004 Mar 1;93(5):639-41
pubmed: 14996599
N Engl J Med. 2017 May 4;376(18):1713-1722
pubmed: 28304224
N Engl J Med. 2017 Sep 21;377(12):1119-1131
pubmed: 28845751
Diabetes Care. 2004 Mar;27(3):781-7
pubmed: 14988302
Angiology. 2019 Jul;70(6):539-546
pubmed: 30384773
Eur Heart J. 2005 Oct;26(19):2032-8
pubmed: 15872029
J Am Coll Cardiol. 2014 Jun 24;63(24):2659-73
pubmed: 24632282
Cardiovasc Diabetol. 2016 Mar 22;15:47
pubmed: 27001495
PLoS One. 2012;7(12):e52036
pubmed: 23300589
Am J Cardiol. 2012 Nov 6;110(9 Suppl):4B-12B
pubmed: 23062567
Heart Lung Circ. 2018 Jun;27(6):716-724
pubmed: 28690023
Eur Heart J. 2016 Jan 14;37(3):267-315
pubmed: 26320110
J Cardiol. 2013 Feb;61(2):113-6
pubmed: 23159207
Nutr Metab Cardiovasc Dis. 2020 Feb 10;30(2):245-253
pubmed: 31744716
JAMA Cardiol. 2016 Sep 1;1(6):718-30
pubmed: 27438381
Ann Intern Med. 2006 Aug 15;145(4):247-54
pubmed: 16908915
N Engl J Med. 2015 Jun 18;372(25):2387-97
pubmed: 26039521
Front Cardiovasc Med. 2021 Dec 02;8:774781
pubmed: 34926622
Diabetes Care. 2007 Feb;30(2):318-24
pubmed: 17259501
JACC Cardiovasc Imaging. 2017 Apr;10(4):451-458
pubmed: 27372016
Lancet Diabetes Endocrinol. 2019 Aug;7(8):618-628
pubmed: 31272931
Eur Heart J. 2010 Nov;31(22):2755-64
pubmed: 20805110
Eur Heart J. 2015 May 14;36(19):1163-70
pubmed: 25586123
Cardiovasc Diabetol. 2021 Jan 12;20(1):19
pubmed: 33435964
J Geriatr Cardiol. 2022 Aug 28;19(8):610-617
pubmed: 36339471
Value Health. 2015 Dec;18(8):969-76
pubmed: 26686780
Circulation. 2003 Oct 28;108(17):2074-81
pubmed: 14530196
Cardiovasc Diabetol. 2018 Aug 31;17(1):122
pubmed: 30170598
Curr Diab Rep. 2019 Mar 2;19(4):18
pubmed: 30826889
Circulation. 2018 Mar 20;137(12):e67-e492
pubmed: 29386200
Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26
pubmed: 17957034
Mol Genet Metab. 2015 Jan;114(1):66-72
pubmed: 25468647
J Am Heart Assoc. 2015 Jan 08;4(1):e001412
pubmed: 25572484
Clin Kidney J. 2022 Mar 10;15(9):1705-1712
pubmed: 36003671
Eur J Clin Invest. 2016 Feb;46(2):189-97
pubmed: 26683265
J Clin Endocrinol Metab. 2010 Jul;95(7):3347-51
pubmed: 20484475
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804
Cardiovasc Diabetol. 2021 Feb 18;20(1):46
pubmed: 33602208
Prev Med. 2016 May;86:99-105
pubmed: 26854766